Imfinzi Combo Cuts Bladder Cancer Death Risk 42% in Phase III VOLGA Trial
AZN is trading near its 52-week low of $153.413 (11% above the low).
Summary
AstraZeneca's VOLGA Phase III trial hit both endpoints: perioperative Imfinzi plus neoadjuvant enfortumab vedotin cut the risk of disease progression, recurrence, missed surgery or death by 49% (EFS HR 0.51) and the risk of death by 42% (OS HR 0.58, p=0.0027) versus cystectomy alone in muscle-invasive bladder cancer patients who can't take or refuse cisplatin. Two-year event-free survival was 64% versus 45%, and two-year overall survival 78% versus 69%. The data were presented at ESMO 2026 and published simultaneously in the New England Journal of Medicine, giving them immediate credibility with oncologists. This matters because roughly half of MIBC patients are cisplatin-ineligible, and the FDA already granted this regimen Priority Review in September 2026 based on these findings — a near-term US approval decision is the next hard event. It extends Imfinzi's franchise across both muscle-invasive and non-muscle-invasive bladder cancer, adding a new revenue stream to an oncology portfolio that has already posted a string of positive Phase III readouts this year.
At the time of this announcement, AZN was trading at $171.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $266B. The 52-week trading range was $153.41 to $212.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.